Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/197992
Type: Artigo de periódico
Title: The Use Of Ultrafiltration For Inflammatory Mediators Removal During Cardiopulmonary Bypass In Coronary Artery Bypass Graf Surgery.
Author: Antunes, Nilson
Dragosavc, Desanka
Petrucci Junior, Orlando
Oliveira, Pedro Paulo Martins de
Kosour, Carolina
Blotta, Maria Heloisa Souza Lima
Braile, Domingo Marcolino
Vieira, Reinaldo Wilson
Abstract: To investigate the effectiveness of ultrafiltration in removing inflammatory mediators released by cardiopulmonary bypass and to correlate ultrafiltration with alterations in organic function according to the Sequential Organ Failure Assessment Score. Forty patients were included and randomized into two groups: no ultrafiltration (n=20; Group I) and ultrafiltration (n=20; Group II). Activated complement 3 and 4, interleukins 1beta, 6, 8 and tumor necrosis factor alfa were measured prior to anesthesia induction (Time 1), 5 minutes before cardiopulmonary bypass (Time 2), in the ultrafiltrated fluid (Time 3), 30 minutes (Time 4), and 6 (Time 5), 12 (Time 6), 24 (Time 7), 36 (Time 8) and 48 (Time 9) hours following cardiopulmonary bypass. Sequential Organ Failure Assessment Score was evaluated at Time 1, 6 and 9. Statistical significance was established at p < 0.05. In the ultrafiltrated fluid, only tumor necrosis factor alfa levels were detected. Levels of activated complement 3 at Times 5 and 7 and activated complement 4 at Times 5 and 6 were significantly higher in the unfiltered Group, and levels of interleukin 6 were higher in the filtered Group at Times 7 and 8. Interleukins 1beta, 8, tumor necrosis factor alfa, and the Sequential Organ Failure Assessment score were not significantly different between the groups. Ultrafiltration significantly filtered tumor necrosis factor alfa but did not influences serum levels of this cytokine. Ultrafiltration with the type of filter used in this study had no effect in organic dysfunction and should be used only for volemic control in patients undergo cardiopulmonary bypass.
Subject: Cardiopulmonary Bypass
Chi-square Distribution
Complement C3a
Complement C4a
Coronary Artery Bypass
Enzyme-linked Immunosorbent Assay
Female
Hemofiltration
Humans
Inflammation Mediators
Interleukin-1beta
Interleukin-6
Interleukin-8
Male
Middle Aged
Multiple Organ Failure
Prospective Studies
Time Factors
Tumor Necrosis Factor-alpha
Rights: aberto
Identifier DOI: 
Address: http://www.ncbi.nlm.nih.gov/pubmed/18820779
Date Issue: -1-Uns- -1
Appears in Collections:Artigos e Materiais de Revistas Científicas - Unicamp

Files in This Item:
File SizeFormat 
pmed_18820779.pdf158.79 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.